Table 4.

Mean (SD) changes in anthropometric, biochemical, and clinical outcomes in patients with nonalcoholic fatty liver disease from baseline at 3 and 6 months after enrolment based on per-protocol analysis.

Variable		n	Change from baseline			Between-group differences
			Control	Intervention	Mean difference (95% CI)		P value (unadjusted)	P value (adjusteda)		Cohen d
Weight, kg
	3 months	101	–1.0 (2.0)	–3.2 (3.1)	2.3 (1.2-3.3)		<.001	<.001		0.88
	6 months	101	–0.7 (2.8)	–4.1 (3.8)	3.5 (2.1-4.8)		<.001	<.001		1.05
Weight, %
	3 months	101	–1.1 (2.4)	–4.0 (3.7)	2.9 (1.7-4.1)		<.001	<.001		0.93
	6 months	101	–0.7 (3.3)	–5.1 (4.5)	4.4 (2.9-6.0)		<.001	<.001		1.11
BMIb, kg/m2
	3 months	101	–0.4 (0.8)	–1.4 (1.1)	1.0 (0.6-1.3)		<.001	<.001		1.04
	6 months	101	–0.3 (1.0)	–1.4 (1.5)	1.1 (0.6-1.6)		<.001	<.001		0.86
Waist circumference, cm
	3 months	99	0.24 (4.69)	–3.57 (5.14)	3.8 (1.8-5.8)		<.001	<.001		0.77
	6 months	99	0.83 (4.4)	–3.24 (5.1)	4.1 (2.2-6.0)		<.001	<.001		0.86
ALTc, IU/L
	3 months	70	–18.7 (26.7)	–37.2 (36.2)	18.5 (3.3-33.8)		.02	.02		0.58
	6 months	98	–10.0 (32.7)	–32.7 (38.4)	22.7 (8.8-36.6)		.002	.002		0.64
ASTd, IU/L
	3 months	71	–9.18 (15.2)	–18.9 (23.8)	9.7 (0.2-19.3)		.046	.04		0.49
	6 months	99	–6.35 (15.3)	–16.1 (24.5)	9.7 (1.6-17.9)		.02	.02		0.47
Systolic blood pressure (mmHg)
	3 months	61	1.1 (12.6)	–13.4 (15.2)	14.5 (7.4-21.6)		<.001	<.001		1.04
	6 months	70	–2.4 (12.4)	–11.8 (15.0)	9.4 (2.9-16.0)		.005	.01		0.68
Diastolic blood pressure (mmHg)
	3 months	61	2.3 (7.7)	–6.1 (10.5)	8.4 (3.8-12.9)		.001	<.001		0.91
	6 months	70	–0.9 (10.0)	–6.5 (9.0)	7.4 (2.8-11.9)		.002	.006		0.78

^aAdjusted for age, gender, and ethnicity.

^bBMI: body mass index.

^eALT: alanine aminotransferase.

^dAST: aspartate aminotransferase.